LogicBio Therapeutics, Inc. (LOGC)

NASDAQ: LOGC · IEX Real-Time Price · USD
1.70
-0.06 (-3.41%)
At close: Jan 21, 2022 4:00 PM
1.72
0.02 (1.18%)
After-hours:Jan 21, 2022 4:00 PM EST
Market Cap56.03M
Revenue (ttm)3.93M
Net Income (ttm)-37.87M
Shares Out32.96M
EPS (ttm)-1.18
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume59,341
Open1.78
Previous Close1.76
Day's Range1.69 - 1.78
52-Week Range1.69 - 9.74
Beta0.97
AnalystsBuy
Price Target14.20 (+735.3%)
Earnings Daten/a

About LOGC

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene thera...

IndustryBiotechnology
IPO DateOct 19, 2018
CEOFrederic Chereau
Employees39
Stock ExchangeNASDAQ
Ticker SymbolLOGC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for LOGC stock is "Buy." The 12-month stock price forecast is 14.20, which is an increase of 735.29% from the latest price.

Price Target
$14.20
(735.29% upside)
Analyst Consensus: Buy

News

LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred Cher...

2 weeks ago - PRNewsWire

LogicBio Therapeutics Provides Business Updates

LEXINGTON, Mass., Dec. 22, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial ...

1 month ago - PRNewsWire

LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones

LEXINGTON, Mass., Nov. 15, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the third quarter ended Septem...

2 months ago - PRNewsWire

LogicBio Therapeutics to Participate in Upcoming Investor Conferences

LEXINGTON, Mass., Nov. 11, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic...

2 months ago - PRNewsWire

Will LogicBio Therapeutics (LOGC) Report Negative Q3 Earnings? What You Should Know

LogicBio Therapeutics (LOGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes...

LEXINGTON, Mass., Oct. 21, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today is slated to present new preclinical data on its GeneRide™ pla...

3 months ago - PRNewsWire

LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children

LEXINGTON, Mass., Oct. 18, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever ...

3 months ago - PRNewsWire

LogicBio Therapeutics to Present New GeneRide™ Data at the European Society of Gene and Cell Therapy Virtual Congress...

LEXINGTON, Mass., Oct. 12, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare a...

3 months ago - PRNewsWire

LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

LEXINGTON, Mass., Sept. 24, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare ...

3 months ago - PRNewsWire

LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

LEXINGTON, Mass., Sept. 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare ...

4 months ago - PRNewsWire

LogicBio Therapeutics (LOGC) Reports Q2 Loss, Lags Revenue Estimates

LogicBio Therapeutics (LOGC) delivered earnings and revenue surprises of -32.00% and -83.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

LogicBio Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones

LEXINGTON, Mass., Aug. 9, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare an...

5 months ago - PRNewsWire

LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021

LEXINGTON, Mass., July 8, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare an...

6 months ago - PRNewsWire

LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatm...

LEXINGTON, Mass., June 2, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare an...

7 months ago - PRNewsWire

LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appoi...

LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare an...

8 months ago - PRNewsWire

LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update

LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical-stage genetic medicine company pioneering gene delivery and gene editing pl...

8 months ago - PRNewsWire

LogicBio Therapeutics Strengthens Management Team with Key Appointments

LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare an...

8 months ago - PRNewsWire

LogicBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

LEXINGTON, Mass., May 4, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and...

8 months ago - PRNewsWire

LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalo...

LEXINGTON, Mass., May 3, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and...

8 months ago - PRNewsWire

LogicBio Therapeutics, CANbridge Ink Partnership For Development Of Gene Therapy Candidates

CANbridge Pharmaceuticals Inc has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics Inc (NASDAQ: LOGC) to develop, manufacture and commercialize gene therapy cand...

8 months ago - Benzinga

CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery ...

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Announces Rare Disease Collaboration with LogicBio and Licenses on Gene Editing & Delivery, Worldwide and in Greater China

8 months ago - Business Wire

LogicBio Therapeutics Announces Clinical and Corporate Updates

LEXINGTON, Mass., April 27, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare ...

8 months ago - PRNewsWire

LogicBio Therapeutics Announces Research Collaboration with Daiichi Sankyo

LEXINGTON, Mass., April 27, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (LogicBio - Nasdaq: LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to a...

8 months ago - PRNewsWire

LogicBio Therapeutics to Present at 2021 Redburn Gene Therapy Summit

LEXINGTON, Mass., March 30, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare ...

9 months ago - PRNewsWire

LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update

LEXINGTON, Mass., March 15, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical- stage genetic medicine company pioneering gene delivery and gene editing...

10 months ago - PRNewsWire